Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
CORAL LAB. TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CORAL LAB. Mar-23 |
TEVA PHARMA Dec-13 |
CORAL LAB./ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 368 | 3,486 | - | |
Low | Rs | 217 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 218.8 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 18.1 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 24.2 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.40 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 433.6 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 3.57 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 82.2% | |
Avg P/E ratio | x | 16.2 | 26.1 | 62.2% | |
P/CF ratio (eoy) | x | 12.1 | 11.4 | 106.6% | |
Price / Book Value ratio | x | 0.7 | 1.5 | 46.1% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 1,045 | 2,761,843 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 111 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 781 | 1,696,422 | 0.0% | |
Other income | Rs m | 69 | 0 | - | |
Total revenues | Rs m | 850 | 1,696,422 | 0.1% | |
Gross profit | Rs m | 39 | 464,566 | 0.0% | |
Depreciation | Rs m | 22 | 137,123 | 0.0% | |
Interest | Rs m | 3 | 33,320 | 0.0% | |
Profit before tax | Rs m | 82 | 294,122 | 0.0% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 18 | -3,591 | -0.5% | |
Profit after tax | Rs m | 64 | 105,974 | 0.1% | |
Gross profit margin | % | 4.9 | 27.4 | 18.0% | |
Effective tax rate | % | 21.6 | -1.2 | -1,773.1% | |
Net profit margin | % | 8.3 | 6.2 | 132.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,235 | 1,145,757 | 0.1% | |
Current liabilities | Rs m | 119 | 999,197 | 0.0% | |
Net working cap to sales | % | 143.0 | 8.6 | 1,654.8% | |
Current ratio | x | 10.4 | 1.1 | 908.4% | |
Inventory Days | Days | 231 | 91 | 254.3% | |
Debtors Days | Days | 1,094 | 96 | 1,140.9% | |
Net fixed assets | Rs m | 508 | 554,089 | 0.1% | |
Share capital | Rs m | 36 | 4,176 | 0.9% | |
Net worth | Rs m | 1,548 | 1,884,403 | 0.1% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 1,743 | 3,876,868 | 0.0% | |
Interest coverage | x | 25.3 | 9.8 | 257.1% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.4 | 0.4 | 102.4% | |
Return on assets | % | 3.9 | 3.6 | 108.3% | |
Return on equity | % | 4.2 | 5.6 | 74.0% | |
Return on capital | % | 5.5 | 4.9 | 112.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 127 | 270,322 | 0.0% | |
From Investments | Rs m | -26 | -95,786 | 0.0% | |
From Financial Activity | Rs m | -64 | -324,269 | 0.0% | |
Net Cashflow | Rs m | 36 | -149,733 | -0.0% |
Compare CORAL LAB. With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare CORAL LAB. With: PARNAX LAB KABRA DRUGS HEMO ORGANIC MEDICAMEN BI SHREE GANESH REMEDIES
It was indeed a volatile trading session for Indian share markets yesterday.